1)McIntyre RS, Berk M, Brietzke E, et al:Bipolar disorders. Lancet 396:1841-1856, 2020[PMID:33278937]
2)Terao T:Latent bipolar depression. Lancet 401:191, 2023[PMID:36681409]
3)寺尾 岳:双極性障害の診かたと治しかた.星和書店,2019
4)Young RC, Biggs JT, Ziegler VE, et al:A rating scale for mania:Reliability, validity and sensitivity. Br J Psychiatry 133:429-435, 1978[PMID:728692]
5)阿部又一郎,Jules Angst:軽躁自記式評価尺度(HCL-33)日本語版試案を作成する.精神科 24:271-276, 2014
6)Hamilton M:A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62, 1960[PMID:14399272]
7)岩本邦弘,稲田俊也:双極性うつ病における抑うつ症状の評価尺度.臨床精神薬理 24:795-802, 2021
8)Hsu CW, Tsai SY, Tseng PT, et al:Differences in the prophylactic effect of serum lithium levels on depression and mania in bipolar disorder:A dose-response meta-analysis. Eur Neuropsychopharmacol 58:20-29, 2022[PMID:35158229]
9)Allen MH, Hirschfeld RM, Wozniak PJ, et al:Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 163:272-275, 2006[PMID:16449481]
10)Chen YB, Liang CS, Wang LJ, et al:Comparative effectiveness of valproic acid in different serum concentrations for maintenance treatment of bipolar disorder:A retrospective cohort study using target trial emulation framework. eClinicalMedicine 54:101678, 2022[PMID:36193173]
11)Chbili C, Bannour S, Khlifi S, et al:Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease. Ann Biol Clin(Paris)72:453-459, 2014[PMID:25119803]
12)Katayama Y, Terao T, Kamei K, et al:Therapeutic window of lamotrigine for mood disorders:A naturalistic retrospective study. Pharmacopsychiatry 47:111-114, 2014
13)Kumar R, Nuñez NA, Prokop LJ, et al:Association of optimal lamotrigine serum levels and therapeutic efficacy in mood disorders:A systematic review. J Clin Psychopharmacol 41:681-686, 2021[PMID:34459434]
14)Kamei K, Terao T, Katayama Y, et al:A predictive model of plasma lamotrigine levels. Pharmacopsychiatry 49:182-185, 2016[PMID:27111132]